← Back to list
Ofatumumab (Arzerra) (CPB 0794, reviewed 2025-10-24)
Effective date
Not stated in the notice
Identified
Aug 12, 2026
Summary
This is historical material: Aetna Clinical Policy Bulletin 0794, Ofatumumab (Arzerra), was reviewed 2025-10-24. The bulletin states Aetna considers ofatumumab medically necessary for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and experimental, investigational or unproven for all other listed indications. The source text does not state an effective date or describe what changed.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.
Get Aetna alertsPolicy Monitoring is free. No card required.
What to do
Action · 3 steps
01Historical material, reviewed 2025-10-24: Billing team, check current applicability of this bulletin before acting on it.
02For HCPCS J9302, confirm that the diagnosis is CLL or SLL, the indications the bulletin lists as medically necessary.
03Read the full policy at the source link to see what changed.
Codes mentioned
J9302C91.10C91.12
Original notice
Ofatumumab (Arzerra) (CPB 0794, reviewed 2025-10-24)
aetna.com · Always check the source before changing claims.
Related changes
See all Aetna changes →Ibritumomab Tiuxetan (Zevalin) (CPB 0659, reviewed 2026-10-15)MediumNo effective date · Medical PolicyAxicabtagene Ciloleucel (Yescarta) (CPB 0924, reviewed 2026-10-09)MediumNo effective date · Medical PolicyHematopoietic Cell Transplantation for Selected Leukemias (CPB 0640, reviewed 2026-09-11)MediumNo effective date · Medical PolicyLisocabtagene Maraleucel (Breyanzi) (CPB 0986, reviewed 2026-09-14)MediumNo effective date · Medical PolicyBrowse every Aetna change in the policy list